Navigation Links
Unigene's Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
Date:12/12/2012

BOONTON, N.J., Dec. 12, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society. The article will be published in the paper version of the journal in the coming months.

This peer reviewed manuscript, entitled, "Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant Human Parathyroid Hormone [rhPTH(1-31)NH2] in Postmenopausal Women with Osteoporosis," provides the full efficacy and safety data from Unigene's Phase 2 clinical study of oral PTH in the treatment of osteoporosis in 97 postmenopausal women.  Kim Henriksen, MSc, PhD, Head of Musculoskeletal Diseases at Nordic Bioscience served as the lead author of the article, which was jointly prepared by authors from Nordic Bioscience, Unigene Laboratories, the Center for Clinical and Basic Research (CCBR) and GlaxoSmithKline (GSK).

Ashleigh Palmer, Unigene's Chief Executive Officer, stated, "We are extremely pleased that a peer-reviewed article detailing the positive Phase 2 results from our oral PTH program was published in such a prestigious scientific journal as Bone.  The data and analysis once again demonstrate the strength of Unigene's proprietary oral peptide drug delivery technology and the clinical potential and commercial viability of our oral PTH analog.  I would like to extend my congratulations to Dr. Henriksen for leading the publication effort and to the entire team of contributors from Nordic Bioscience, CCBR, GSK and Unigene for their tremendous wor
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
2. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
3. uniQure Initiates Phase I in Acute Intermittent Porphyria
4. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
5. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
6. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
7. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
8. Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
9. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
10. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
11. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 20, 2015 International Isotopes Inc. (OTCQB: ... shareholders with the following update on its business ... Historically, INIS has produced and sold ... models of sealed sources for medical and industrial ... therapy, security examination, and radiography.  Due to technical ...
(Date:4/20/2015)... KANNAPOLIS, N.C. , April 20, 2015 /PRNewswire/ ... managed care organization that focuses on high-tech, high-touch ... for delivering behavioral health services during the National ... The event, which takes place April 20–22, 2015, ... in Orlando, Fla. , attracts ...
(Date:4/20/2015)... , April 20, 2015 Eli Lilly ... the investigational medicine ixekizumab was statistically superior to placebo ... (PsA), as demonstrated by the proportion of patients achieving ... assessment that represents a 20 percent reduction in disease ... of Rheumatology response criteria. During the 24-week, Phase 3 ...
Breaking Medicine Technology:International Isotopes Inc. Provides Shareholders With An Update On New Opportunities And Positive Developments Within Its Existing Business Segments 2International Isotopes Inc. Provides Shareholders With An Update On New Opportunities And Positive Developments Within Its Existing Business Segments 3International Isotopes Inc. Provides Shareholders With An Update On New Opportunities And Positive Developments Within Its Existing Business Segments 4International Isotopes Inc. Provides Shareholders With An Update On New Opportunities And Positive Developments Within Its Existing Business Segments 5Cardinal Innovations Highlights its Managed Care Model During National Council for Behavioral Health's Annual Conference 2Cardinal Innovations Highlights its Managed Care Model During National Council for Behavioral Health's Annual Conference 3Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 2Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 3Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 4
... LAUSANNE, Switzerland, July 21 Debiopharm Group,(Debiopharm), ... focus on the development of prescription drugs that ... agency for therapeutic products,Swissmedic, has issued a marketing ... prescribed for a reversible reduction,of serum testosterone to ...
... Ueno, Ltd. announced on July 17 that as a phase 1 ... by our company as a therapeutic drug of androgenetic alopecia (male ... , The phase 1 clinical study of ... study and 5-day repeated-dose study. Since no serious adverse event occurred ...
Cached Medicine Technology:Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations 2Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations 3R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023 2R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023 3
(Date:4/20/2015)... (PRWEB) April 20, 2015 Mutare ... has secured nationally-renowned Gastroenterologist Lawrence Kosinski, MD, MBA, ... , Dr. Kosinski brings a unique combination of ... to the Mutare Health team as ... communication, collaboration, and quality of care in the ...
(Date:4/20/2015)... Danbury, Connecticut (PRWEB) April 20, 2015 ... that Moreen Donahue, DNP, RN, NEA-BC, FAAN who ... for Nursing Education and Research in September 2014, ... Chief Nursing Officer to lead the development of ... In this newly created role, Donahue will be ...
(Date:4/20/2015)... April 20, 2015 Novatus, a ... further expanded its service level to the growing ... in Amsterdam and Paris. After a rigorous ... sophisticated levels of resilience, security and operational expertise, ... milestone for Novatus as we expand our footprint ...
(Date:4/20/2015)... Southfield, MI (PRWEB) April 20, 2015 ... products is a personal matter that many customers would prefer ... offering as of March 30th a discreet delivery method allowing ... have them arrive at their home without fear of a ... This discreet shipping method is available now on all orders ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 America’s ... the U.S. health insurance industry, is seeking greater ... the recent controversy involving surgical tools called power ... U.S. Senator Robert Casey (D-PA) dated April 14th, ... uterine morcellation point to “serious gaps in the ...
Breaking Medicine News(10 mins):Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 2Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 3Health News:Nursing Executive to Develop and Lead Nursing Leadership Program at Western Connecticut Health Network 2Health News:Novatus Expands into European Data Centers 2Health News:Advance Home Care Supply Proud to Offer Discreet Delivery For All Orders 2Health News:Advance Home Care Supply Proud to Offer Discreet Delivery For All Orders 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 4
... years,since the nation,s capital was stunned by terrorist ... are we any better prepared now than we,were ... Hospital,Center will answer the question, Tuesday evening, October ... READY?" -- as they present the,Washington Hospital Center,s ...
... Renowned Therapist Challenges Modern Psychology and Explodes Myths of ,Why ... ... children have a,genetic predisposition to bad behavior and are more difficult to ... parents, has,been the cross parents have had to bear for decades, placing ...
... October 29, 2007 - A new study published in ... self-reported active epilepsy and health-related quality of life among ... data collected in the 2003 California Health Interview Survey ... finds that in 2003, almost 300,000 (1.2 percent) adults ...
... - Monthly blog will appear in conjunction with ... 29 The Kellogg School,of Management at Northwestern ... monthly blog developed by David Dranove, the Kellogg ... Management.,"Code Red" is accessible at the following link:, ...
... (Amex: PRZ ), one of the nation,s leading ... announced that at its,2007 Annual Meeting of Stockholders held ... of board members and the,ratification of Brimmer, Burek & ... ending December 31, 2007. Re-elected board members, who ...
... Pharmaceuticals,Inc., which discovers and develops novel antiviral therapeutics ... of Steven D.,Skolsky as its President and Chief ... of the Board of Directors. "Sequoia is ... as Steven Skolsky," said Chris Mirabelli, Chairman of ...
Cached Medicine News:Health News:Are We Ready? Washington Hospital Center Sets Precedents in Preparedness for 9/11-Style Attacks 2Health News:Bad Children Can Happen to Good Parents: A Survival Manual for Parents of Difficult Children by Norman E. Hoffman, Ph.D. 2Health News:Bad Children Can Happen to Good Parents: A Survival Manual for Parents of Difficult Children by Norman E. Hoffman, Ph.D. 3Health News:Kellogg School of Management Announces 'Code Red' 2Health News:PainCare Announces Results of 2007 Annual Meeting of Stockholders 2Health News:PainCare Announces Results of 2007 Annual Meeting of Stockholders 3Health News:Sequoia Pharmaceuticals Announces Appointment of Steven D. Skolsky as Chief Executive Officer 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: